Key facts
- Zero Point Five Therapeutics’s last known valuation is $39.0M (May 2025).
- It has raised $16.0M across 2 recorded rounds; the latest was Seed Round ($4.3M) in Apr 2025.
- Notable investors include TEDCO, Fintech Next, Next Act Fund, Portfolia.
- Zero Point Five Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently Apr 2025 ($4.3M sold to 10 investors).
- Status: Privately Held (backing).
Investors
4- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Zero Point Five Therapeutics
Funding rounds
2 roundsAbout Zero Point Five Therapeutics
Developer of therapeutics designed to treat soil-transmitted helminthiasis. The company focuses on developing a therapy for a neglected disease to offer medication to underserved communities, enabling healthcare professionals to provide medical care to underprivileged communities.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2018
- Ownership
- Privately Held (backing)
Zero Point Five Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zero Point Five Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zero Point Five Therapeutics in its N-PORT filings yet. We sweep new filings monthly.